Here’s what you should know:
1. INN-108 is an oral pediatric ulcerative colitis oral therapy. It consists of two moieties, an ulcerative colitis agent and a rheumatoid arthritis agent. The agents are “covalently azo-bonded.” They separate in the patient’s colon.
2. Innovate Biopharmaceuticals completed two phase I trials for INN-108. Innovate will start a phase II trial in 2018. Innovate is developing a liquid oral formula of INN-108 for pediatric ulcerative colitis patients.
3. If the FDA approves INN-108, Innovate will hold market exclusivity for seven years.
More articles on gastroenterology:
This minimally invasive test could change gastroesophageal reflux disease screening
4 Baylor physicians meet with Rep. Gene Green
Florida jury finds gastroenterologist not liable in alleged ‘slapdash colonoscopy’ trial — 6 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.